KESTRA MEDICAL TECHNOLOGIES Business Summary

Kestra Medical Technologies (NASDAQ: KMTS) operates a commercial-stage business model focused on its integrated Cardiac Recovery System, generating revenue primarily through a recurring, prescription-based service model for the ASSURE® Wearable Cardioverter Defibrillator (WCD). The company’s primary business segments encompass wearable therapeutic devices and digital health monitoring, supported by the cloud-based CareStation™ platform and the ASSURE patient application. With broad insurance coverage established for over 200 million lives, Kestra is guiding for approximately $88 million in revenue for fiscal year 2026, representing nearly 50% year-over-year growth. Direct competitors include ZOLL Medical (LifeVest), iRhythm Technologies, and Element Science. Kestra differentiates itself as a high-growth disruptor to the legacy incumbent, ZOLL, by offering a modern, dual-sensor detection algorithm and a garment-like form factor designed to maximize patient compliance and minimize false therapeutic shocks. The company is led by President and CEO Brian Webster, a veteran executive who previously served as CEO of Physio-Control, where he oversaw its $1.28 billion acquisition by Stryker. The executive leadership team includes Chief Financial Officer Vaseem Mahboob and Chief Business Officer Timothy Moran, a medtech veteran appointed in late 2025 to accelerate commercial scaling and payor engagement. Kestra was founded in 2014 with strategic backing from Bain Capital and completed a $202 million initial public offering in March 2025. The company’s institutional investor base includes Andera Partners, Ally Bridge Group, and Longitude Capital. Strategic oversight is provided by a board of directors that includes Chairman Jeffrey Schwartz and independent directors such as Raymond W. Cohen, CEO of Axonics, and digital health expert Dr. Elizabeth Kwo, ensuring a leadership pedigree deeply rooted in cardiac rhythm management and commercial medical technology.